• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Kirk McDonald Appointed to Ziff Davis Board of Directors

    11/16/23 4:35:00 PM ET
    $ELAN
    $ZD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Telecommunications Equipment
    Telecommunications
    Get the next $ELAN alert in real time by email

    Ziff Davis, Inc. (NASDAQ:ZD), today announced the appointment of Kirk McDonald to its Board of Directors, effective November 15, 2023. McDonald is a highly accomplished executive with extensive experience and a career spanning more than three decades in media, technology, and advertising.

    "We are thrilled to welcome Kirk to our Board of Directors," said Ziff Davis Board Chair Sarah Fay. "As an industry veteran known for his business leadership, he will be an asset to Ziff Davis."

    McDonald serves as CEO of GroupM North America, a leading media investment agency. He announced that he will leave the role at year end. Prior to this, he was Chief Business Officer of Warner Media's Xandr when it was a division of AT&T. He was also President of Pubmatic, and has held executive level leadership roles at Time Inc., the Aquantive division of Microsoft, and CNET Networks. McDonald currently serves on the board of Elanco (NYSE:ELAN), and is a founding member of the Black Executive CMO Alliance. He also serves on the boards of directors of industry organizations including the Ad Council (as co-chair), the Paley Center for Media, and the Advertising Week Advisory Council. An alumnus of the City College of New York, Mr. McDonald majored in English as an undergraduate.

    "Kirk is widely respected in our industry, and has been a leader and innovator across a range of companies in the media and advertising ecosystem," said Ziff Davis CEO Vivek Shah.

    "I am delighted to be joining the Ziff Davis Board of Directors," McDonald said. "I look forward to working with Vivek and the entire Ziff Davis team across its portfolio of leading brands."

    About Ziff Davis

    Ziff Davis (NASDAQ:ZD) is a vertically focused digital media and internet company whose portfolio includes leading brands in technology, shopping, gaming and entertainment, connectivity, health, cybersecurity, and martech. For more information, visit www.ziffdavis.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231116449936/en/

    Get the next $ELAN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ELAN
    $ZD

    CompanyDatePrice TargetRatingAnalyst
    Elanco Animal Health Incorporated
    $ELAN
    6/26/2025Mkt Perform → Outperform
    William Blair
    Ziff Davis Inc.
    $ZD
    4/22/2025$33.00Overweight → Neutral
    Analyst
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2024$18.00Buy
    UBS
    Elanco Animal Health Incorporated
    $ELAN
    12/2/2024$14.00Market Perform
    Leerink Partners
    Elanco Animal Health Incorporated
    $ELAN
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    Ziff Davis Inc.
    $ZD
    5/2/2024$70.00Neutral → Overweight
    JP Morgan
    Elanco Animal Health Incorporated
    $ELAN
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    Elanco Animal Health Incorporated
    $ELAN
    12/19/2023$17.00Buy
    Jefferies
    More analyst ratings

    $ELAN
    $ZD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/11/25 5:13:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/7/25 4:21:21 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kretzmer W Brian bought $25,029 worth of Common Stock $0.01 Par Value (653 units at $38.33), increasing direct ownership by 5% to 12,968 units (SEC Form 4)

      4 - ZIFF DAVIS, INC. (0001084048) (Issuer)

      3/6/25 6:01:33 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications

    $ELAN
    $ZD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

      7/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection

      TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8.100% virus neutralization against 33 current field isolates.1Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines.GREENFIELD, Ind., July 9, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan

      7/9/25 8:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziff Davis Completes Three Acquisitions in Q2 2025

      Ziff Davis, Inc. (NASDAQ:ZD), announced today that it completed three acquisitions in the second quarter of 2025. The acquisitions listed below grow Ziff Davis' global customer base, provide access to new markets and expand the company's product lineup. Forensic and Compliance Systems Cybersecurity & Martech Email Industries Cybersecurity & Martech Well+Good Health & Wellness Terms of the individual acquisitions were not disclosed, and the financial impact to Ziff Davis is not expected to be material with respect to the acquisitions. About Ziff Davis Ziff Davis (NASDAQ:ZD) is a vertically focused digital media and internet company whose

      7/3/25 7:00:00 AM ET
      $ZD
      Telecommunications Equipment
      Telecommunications

    $ELAN
    $ZD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF ACCOUNTING OFFICER Meer James M covered exercise/tax liability with 1,161 shares, decreasing direct ownership by 2% to 58,103 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      7/8/25 4:19:02 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, MANUFACTURING AND QUALITY Mcardle Grace covered exercise/tax liability with 4,346 shares, decreasing direct ownership by 5% to 76,049 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      7/8/25 4:17:14 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Anand Kapila K

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      7/2/25 4:16:24 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    $ZD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elanco Animal Health upgraded by William Blair

      William Blair upgraded Elanco Animal Health from Mkt Perform to Outperform

      6/26/25 7:49:03 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziff Davis downgraded by Analyst with a new price target

      Analyst downgraded Ziff Davis from Overweight to Neutral and set a new price target of $33.00

      4/22/25 7:23:44 AM ET
      $ZD
      Telecommunications Equipment
      Telecommunications
    • UBS initiated coverage on Elanco Animal Health with a new price target

      UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

      12/9/24 7:40:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    $ZD
    SEC Filings

    See more
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      6/26/25 4:01:32 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Elanco Animal Health Incorporated

      SD - Elanco Animal Health Inc (0001739104) (Filer)

      5/30/25 10:00:37 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      5/28/25 7:30:32 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    $ZD
    Leadership Updates

    Live Leadership Updates

    See more
    • Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

      The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

      6/5/25 7:45:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

      GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

      5/28/25 7:25:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziff Davis Appoints John Ingram as SVP, Corporate Finance and Development

      Ziff Davis, Inc. (NASDAQ:ZD), has named John Ingram Senior Vice President, Corporate Finance and Development, overseeing global activities related to mergers and acquisitions and working with corporate leadership on strategic planning, capital allocation, capital markets transactions, and stakeholder engagement. He will report to Bret Richter, Chief Financial Officer of Ziff Davis. Mr. Ingram brings more than 18 years of M&A and corporate finance experience with a focus on the media and technology sectors. Prior to joining Ziff Davis, Mr. Ingram co-founded Aliri Capital, an independent sponsor focused on investing in lower middle market B2B services and tech-enabled services companies. Be

      4/21/25 9:00:00 AM ET
      $ZD
      Telecommunications Equipment
      Telecommunications

    $ELAN
    $ZD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ziff Davis Inc.

      SC 13G/A - ZIFF DAVIS, INC. (0001084048) (Subject)

      11/12/24 5:57:23 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications
    • Amendment: SEC Form SC 13G/A filed by Ziff Davis Inc.

      SC 13G/A - ZIFF DAVIS, INC. (0001084048) (Subject)

      11/4/24 2:15:05 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications
    • SEC Form SC 13G filed by Ziff Davis Inc.

      SC 13G - ZIFF DAVIS, INC. (0001084048) (Subject)

      10/31/24 11:55:01 AM ET
      $ZD
      Telecommunications Equipment
      Telecommunications

    $ELAN
    $ZD
    Financials

    Live finance-specific insights

    See more
    • Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

      7/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziff Davis Reports First Quarter 2025 Financial Results and Reaffirms 2025 Guidance

      Ziff Davis, Inc. (NASDAQ:ZD) ("Ziff Davis" or "the Company") today reported unaudited financial results for the first quarter ended March 31, 2025. "We are pleased with our overall first quarter performance, which surpassed our internal targets," said Vivek Shah, Chief Executive Officer of Ziff Davis. "The combination of accelerating revenue growth, a healthy M&A cadence, and our active share buyback program has us optimistic about our prospects for the balance of the year." FIRST QUARTER 2025 RESULTS Q1 2025 quarterly revenues increased 4.5% to $328.6 million compared to $314.5 million for Q1 2024. Income from operations decreased to $35.1 million compared to $35.9 million for Q1 20

      5/8/25 6:00:00 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care